Clinical Trial Update: Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a completed Phase 2 clinical trial evaluating oral SCIO-469 in relapsed, refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SCIO-469

Snippet

Sponsor: Scios, Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED